Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

10.85USD
2:23pm EST
Change (% chg)

$0.15 (+1.40%)
Prev Close
$10.70
Open
$10.75
Day's High
$10.90
Day's Low
$10.65
Volume
144,695
Avg. Vol
240,221
52-wk High
$25.40
52-wk Low
$8.68

Chart for

About

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated... (more)

Overall

Beta: 2.50
Market Cap(Mil.): $724.54
Shares Outstanding(Mil.): 67.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results

Nov 07 2017

BRIEF-Alder Biopharmaceuticals Q2 loss per share $1.48

* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results

Aug 08 2017

BRIEF-Alder Biopharmaceuticals announces commencement of public offering of common stock

* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock

Jul 11 2017

Alder's shares tumble as migraine drug data disappoints

Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.

Jun 27 2017

UPDATE 4-Alder's shares tumble as migraine drug data disappoints

* Shares fall as much as 26 pct to 2 1/2 yr-low (Adds analyst comment, updates shares)

Jun 27 2017

BRIEF-Alder Biopharmaceuticals announces positive eptinezumab phase 3 results

* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

Jun 27 2017

Alder's migraine drug meets main goal in late-stage study

June 27 Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.

Jun 27 2017

Earnings vs. Estimates